Skip to main content
SpringerLink
Log in

Mitoxantrone reduces relapse rate and slows disease progression in worsening multiple sclerosis

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 2004; 18(6): 379–96

    Article  PubMed  CAS  Google Scholar 

  2. Weinstock-Guttman B, Bakshi R. Combination therapy for multiple sclerosis: the treatment strategy of the future? CNS Drugs 2004; 18(12): 777–92

    Article  PubMed  CAS  Google Scholar 

  3. Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360(9350): 2018–25

    Article  PubMed  Google Scholar 

  4. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria [see comments]. J Neurol Neurosurg Psychiatry 1997; 62(2): 112–8

    Article  PubMed  CAS  Google Scholar 

  5. Crossley RJ. Clinical safety and tolerance of mitoxantrone. Semin Oncol 1984; 11(3 Suppl. 1): 54–8

    PubMed  CAS  Google Scholar 

  6. Edan G, Brassat D, Clanet M, et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients [abstract no. S23.005]. Neurology 2002; 58 Suppl. 3: A168

    Google Scholar 

  7. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002 Sep 24; 59: 909–13

    Article  PubMed  CAS  Google Scholar 

  8. Avasarala JR, Cross AH, Clifford DB, et al. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003 Feb; 9(1): 59–62

    Article  PubMed  CAS  Google Scholar 

  9. Serono. Novantrone®: mitoxantrone for injection concentrate (US) [online]. Available from URL: http://www.novantrone.com/pdf/novantrone_prescribing_info.pdf[Accessed 2004 Nov 26]

  10. Schleyer E, Kamischke A, Kaufmann CC, et al. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. Leukemia 1994; 8(3): 435–40

    PubMed  CAS  Google Scholar 

  11. Smyth JF, Macpherson JS, Warrington PS, et al. The clinical pharmacology of mitoxantrone. Cancer Chemother Pharmacol 1986; 17(2): 149–52

    Article  PubMed  CAS  Google Scholar 

  12. Becker CC, Gidal BE, Fleming JO. Immunotherapy in multiple sclerosis, part 2. Am J Health Syst Pharm 1995; 52(19): 2105–20

    PubMed  CAS  Google Scholar 

  13. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [published erratum appears in Neurology 2002; 59 (3): 480]. Neurology 2002; 58(2): 169–78

    Article  PubMed  CAS  Google Scholar 

  14. Mikol DD, Bernitsas E. Safety and tolerability of mitoxantrone plus dexrazoxane therapy in multiple sclerosis patients [abstract no. P06.084]. Neurology 2002; 58 Suppl. 3: A459–60

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mitoxantrone reduces relapse rate and slows disease progression in worsening multiple sclerosis. Drugs Ther. Perspect 21, 1–4 (2005). https://doi.org/10.2165/00042310-200521030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200521030-00001

Search

Navigation